Petra Furstova

Petra Furstova

Auto-generated profile, based on publicly available information

Petra Furstova

National Institute of Mental Health, Klecany, Czech Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in European Psychiatry
Verified
Journal Article
Open access
PDF file
KVKristyna Vochoskova
Kristyna Vochoskova
SMSean R. McWhinney
Sean R. McWhinney
MFMarketa Fialova
Marketa Fialova
MKMarian Kolenic
Marian Kolenic
FSFilip Spaniel
Filip Spaniel
THTomas Hajek
Tomas Hajek
Background: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. Methods: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors. Results: Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications. Conclusions: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

1 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SSStella M. Sánchez
Stella M. Sánchez
TKThomas R. Knösche
Thomas R. Knösche
PFPetra Fürstová
Petra Fürstová
AŠAntonín Škoch
Antonín Škoch
FSFilip Spaniel
Filip Spaniel
JHJaroslav Hlinka
Jaroslav Hlinka
BACKGROUND AND HYPOTHESIS: Schizophrenia is associated with widespread neuroanatomical abnormalities affecting both grey matter and white matter (WM). Early symptoms are often linked to dysfunctions in the frontal cortex and the temporal lobe. This study investigates WM disruptions and explores how structural connectivity (SC) may contribute to the underlying mechanisms of the disorder. STUDY DESIGN: We analysed SC derived from diffusion MRI in 127 patients experiencing their first episode of schizophrenia (FES group), compared with healthy controls. Focusing on the fronto-parietal-temporal network, we examined SC across three hierarchical levels: network, node, and connection. SC metrics were compared between groups using 3-factor ANCOVA, accounting for relevant covariates. We also investigated associations between SC metrics and core positive symptoms using non-parametric correlations. RESULTS: The FES group showed significantly reduced average SC strength and global efficiency within the fronto-parietal-temporal network. At the nodal level, SC strength was significantly lower in the left inferior and middle temporal gyri (L.ITG, L.MTG), and in the right inferior parietal gyrus (R.IPG) and temporal pole (R.TP). No significant group differences emerged at the connection level. Notably, SC strength in the R.IPG was negatively correlated with Conceptual Disorganisation scores. CONCLUSIONS: Our findings reveal global and regional SC disruptions in early psychosis, particularly in areas supporting cognitive, language, and executive functions. The observed association between R.IPG connectivity and Conceptual Disorganisation supports the link between disrupted SC and formal thought disorder, reinforcing the role of impaired structural integration in early psychosis.

4 August 2026 in Schizophrenia Research
Verified
Journal Article
Open access
EBEduard Bakstein
Eduard Bakstein
JKJan Kudelka
Jan Kudelka
JSJakub Schneider
Jakub Schneider
ASAndrea Slovakova
Andrea Slovakova
MFMarketa Fialova
Marketa Fialova
FSFilip Spaniel
Filip Spaniel
Predicting long-term outcomes in first-episode schizophrenia (FES) remains difficult, despite being especially important early in the illness, when timely intervention is most critical. It also remains unclear how much data from the initial phase of illness is required to improve prognostic accuracy. We analysed 68 FES patients assessed at baseline (V1; mean 0.5 years post-onset), one-year follow-up (V2; mean 1.2 years), and outcome (V3; mean 4.9 years). Elastic-net models were trained to predict three V3 outcomes - negative symptoms (PANSS Negative factor; Wallwork/Fortgang), global functioning (GAF), and quality of life (WHOQOL-BREF psychological domain) - using either V1 predictors alone (23 variables) or V1 + V2 combined (43 variables). Performance was evaluated using nested cross-validation on held-out data. With V1 + V2 predictors, all three outcomes were predicted at statistically significant levels: PANSS Negative R2 = 0.22 (driven by log(DUP), PANSS Negative at V1/V2, and PANSS Disorganised at V2); WHOQOL-BREF Psychological Health R2 = 0.22 (driven by WHOQOL Psychological Health and GAF at V2); and GAF R2 = 0.14 (driven by GAF, PANSS Positive, WHOQOL Psychological Health at V2, and hospitalisation burden). With V1 predictors alone, only PANSS Negative showed meaningful predictive power (R2 = 0.15); GAF and WHOQOL-BREF did not outperform the intercept-only baseline. Long-term functioning and quality of life in FES cannot be predicted from first-episode data alone; at least one year of follow-up is required, suggesting post-onset changes shape these outcomes. Negative symptoms are an exception: comparatively stable after initial treatment and predictable from baseline, with past symptomatology along with DUP selected as predictors - indicating stronger persistency and predictability than in the other two investigated outcomes.

25 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
EBEduard Bakstein
Eduard Bakstein
JKJan Kudelka
Jan Kudelka
JSJakub Schneider
Jakub Schneider
ASAndrea Slovakova
Andrea Slovakova
MFMarketa Fialova
Marketa Fialova
FSFilip Spaniel
Filip Spaniel
BACKGROUND: Predicting long-term outcomes in first-episode schizophrenia (FES) remains difficult, despite being especially important early in the illness, when timely intervention is most critical. Many potential predictors have been studied, but few are reliable enough to guide early treatment decisions. It also remains unclear how much data from the initial phase of illness is required to improve prognostic accuracy. METHODS: We analysed 68 patients with first-episode schizophrenia (FES) assessed at baseline (V1; mean 0.5 years post-onset, YPO), one-year follow-up (V2; mean 1.2 YPO), and outcome (V3; mean 4.9 YPO). We trained elastic-net models to predict three V3 outcomes—negative symptoms (PANSS Negative factor; Wallwork/Fortgang), global functioning (GAF), and quality of life (WHOQOL-BREF psychological domain)—using either 23 V1 predictors alone or V1 predictors plus V2 data (43 predictors). Performance was evaluated with nested cross-validation on held-out data. RESULTS: Using predictors from the first year (V1+V2), we achieved statistically significant out-of- sample prediction for all three V3 outcomes: PANSS Negative factor (Wallwork/Fortgang) R 2 =0.22— driven mainly by log(DUP), PANSS Negative at V1/V2, and PANSS Disorganized at V2; WHOQOL-BREF Psychological Health R 2 =0.22—driven mainly by WHOQOL Psychological Health at V2 and GAF at V2; and GAF R 2 =0.14—driven mainly by GAF at V2, PANSS Positive at V2, WHOQOL Psychological Health at V2, and hospitalization burden (before V1 and between V1–V2). With baseline-only predictors (V1), only PANSS Negative showed meaningful predictive power (R 2 =0.15); GAF and WHOQOL-BREF did not outperform the intercept-only baseline. CONCLUSION: In FES, long-term functioning (GAF) and quality of life (WHOQOL-BREF) can not be predicted well from first-episode (V1) measures; at least an additional 1 year of follow-up is needed, implying these outcomes are driven by changes after onset that V1 misses. Negative symptoms differ: they are comparatively stable after initial antipsychotic treatment, and duration of untreated psychosis is their strongest predictor beyond baseline severity—consistent with early biology and treatment timing shaping their level and persistence. These contrasting patterns indicate different outcome phenotypes.